Skip Navigation LinksHome > March 2011 - Volume 54 - Issue 1 > Breast Cancer: Adjuvant Modalities
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e31820838df
Breast Cancer: Pursuing State of the Art Care

Breast Cancer: Adjuvant Modalities

SAKR, BACHIR J. MD*; DIZON, DON S. MD

Collapse Box

Abstract

The mortality rate due to breast cancer has declined over the preceding decades to a great extent, secondary to the development and use of effective adjuvant therapy. Tamoxifen remains the standard of care in premenopausal women, whereas aromatase inhibitors have become standard therapy after menopause for women with hormone-sensitive disease. Tumor gene profiling assays are being increasingly used to identify women with hormone-sensitive disease, who would benefit from adjuvant chemotherapy. For those women with hormone negative cancer, systemic chemotherapy provides substantial reduction in the risk of disease recurrence and death.

© 2011 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.